BRIDGEWATER, N.J.--(BUSINESS WIRE)--Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced final data from three separate Phase II trials involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein inhibitor (MTP-I) small molecule drug. The final data was recently presented at the American Diabetes Association’s “69th Scientific Sessions” in New Orleans, LA on June 7, 2009 and the International Symposium on Atherosclerosis (ISA) in Boston, MA on June 15, 2009.
